AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical ...
BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...
"Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and ...
DOR/ISL is currently at the pre-registration stage of development in the US and is expected to launch in this market in 2026, if approved.
Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...
Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - ...
It’s been a topsy-turvy week for Novo Nordisk, makers of the popular weight loss drugs Ozempic and Wegovy. Fresh off the heels of a disappointing trial for one experimental drug, the company has just ...
PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar, ...
AI could review data sets to assist clinical scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results